Bausch & Lomb Corp (NYSE: BLCO)

Bausch + Lomb is a leading global eye health company dedicated to protecting and enhancing the gift of sight for people around the world. The company develops, manufactures and markets a broad portfolio of approximately 400 products that span contact lenses, intraocular lenses, surgical systems and devices, vitamin and mineral supplements, lens care solutions, prescription eye medications and over the counter eye drops. Operating in roughly 100 countries, Bausch + Lomb functions as a fully integrated eye health business that serves the full lifecycle of vision care from birth through later life.

Revenue is generated primarily from the sale of products in the eye health therapeutic areas, including branded pharmaceuticals, generic pharmaceuticals, over the counter vitamin and supplement products, and medical devices such as contact lenses, intraocular lenses and ophthalmic surgical equipment. Additional revenue streams arise from alliance and service income, licensing and co promotion arrangements, and contract manufacturing fees. The company’s sales are made directly or indirectly to customers worldwide, with product mix driving both volume and pricing dynamics.

The company operates through the following segments.

• Vision Care: This segment encompasses the contact lens and consumer eye care businesses. It offers a wide range of contact lenses including daily disposable, frequent‑replacement and therapeutic lenses such as Bausch + Lomb INFUSE®, Biotrue® ONEday, PureVision®, SofLens® and Bausch + Lomb ULTRA®. The consumer eye care division provides lens‑care solutions (Biotrue®, Renu®, Boston®), over the counter eye drops (Lumify®, Soothe®, Artelac®, Alaway®, Mioclear®) and vitamin supplements (PreserVision®, Ocuvite®).

• Pharmaceuticals: This segment supplies postoperative treatment products and generic pharmaceuticals for various eye conditions including glaucoma, inflammation, ocular hypertension, dry eye and retinal diseases. Key branded products are MIEBO®, XIIDRA®, Vyzulta®, Lotemax®, Prolensa® and Minims®, complemented by a portfolio of generic ophthalmic formulations.

• Surgical: This segment provides medical‑device equipment, consumables and technologies for cataract, corneal, vitreous and retinal procedures. It includes intraocular lenses and delivery systems, phacoemulsification platforms, surgical instruments and devices such as Akreos®, AMVISC®, IC 8 Apthera®, Crystalens®, enVista® IOLs, Eyetelligence® Surgical Planning Software, Millennium®, Stellaris Elite® vision‑enhancement system, Synergetics®, ClearVisc®, StableVisc®, Storz® ophthalmic instruments, VICTUS® femtosecond laser, Teneo®, Eyefill® and Zyoptix®.

Bausch + Lomb holds a leading position in the global eye health market, competing against other large ophthalmology companies through its diversified product line and integrated development, manufacturing and commercial capabilities. Its competitive advantage stems from a broad portfolio that covers vision care, pharmaceuticals and surgical devices, supported by substantial research and development investment and a presence in approximately 100 countries.

The company serves a varied customer base that includes individual consumers, patients, eye care professionals such as optometrists and ophthalmologists, hospitals, surgical centers, distributors and retail outlets worldwide. Specific customer names are not disclosed in the filing.